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SUMMARY
ADHERE was a randomized, open-label, Phase IV study comparing renal
function at Week 52 postkidney transplant, in patients who received prolonged-
release tacrolimus-based immunosuppressive regimens. On Days 0–27, patients
received prolonged-release tacrolimus (initially 0.2 mg/kg/day), corticosteroids,
and mycophenolate mofetil (MMF). Patients were randomized on Day 28 to
receive either prolonged-release tacrolimus plus MMF (Arm 1) or prolonged-
release tacrolimus (≥25% dose reduction on Day 42) plus sirolimus (Arm 2).
The primary endpoint was glomerular filtration rate by iohexol clearance
(mGFR) at Week 52. Secondary endpoints included eGFR, creatinine clearance
(CrCl), efficacy failure (patient withdrawal or graft loss), and patient/graft
survival. Tolerability was analyzed. The full-analysis set comprised 569 patients
(Arm 1: 287; Arm 2: 282). Week 52 mean mGFR was similar in Arm 1 versus
Arm 2 (40.73 vs. 41.75 ml/min/1.73 m2; P = 0.405), as were the secondary end-
points, except composite efficacy failure, which was higher in Arm 2 versus 1
(18.2% vs. 11.5%; P = 0.002) owing to a higher postrandomization withdrawal
rate due to adverse events (AEs) (14.4% vs. 5.2%). Results from this study show
comparable renal function between arms at Week 52, with fewer AEs leading to
study discontinuation with prolonged-release tacrolimus plus MMF (Arm 1)
versus lower dose prolonged-release tacrolimus plus sirolimus (Arm 2).
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Introduction
For over 20 years, calcineurin inhibitors (CNIs), such
as tacrolimus, have been the mainstay of immunosup-
pressive protocols for kidney transplantation, reducing
the risk of graft failure and patient mortality com-
pared with other therapies in both clinical trials and
clinical settings [1,2]. Although short-term outcomes
in Europe are satisfactory, ten-year kidney graft sur-
vival rates of approximately 56% [3] suggest that
there is scope for further improvement in long-term
outcomes for these patients. The causes of graft loss
are diverse [4–6] and include some risk factors that
could be managed through optimization of the
immunosuppressive regimen [4,7–9]. Approaches taken
to explore regimen optimization include the addition
of other immunosuppressive treatments to CNIs, espe-
cially those with complementary mechanisms of action
and different adverse event (AE) profiles [10–12].
Tacrolimus in combination with mycophenolate mofe-
til (MMF) is an effective immunosuppressive regimen
for kidney transplant recipients [13]. The combination
of tacrolimus and sirolimus, an inhibitor of mam-
malian target of rapamycin, has been shown to pro-
vide effective immunosuppression [14–17] and has
been reported to be renal-sparing in some combina-
tions [18], although sirolimus-related side effects have
been associated with tolerability concerns and frequent
discontinuations [16,19,20]. The strong synergistic
immunosuppressive effect of tacrolimus plus sirolimus
permits dose reduction of tacrolimus when used in
combination with sirolimus. However, CNI avoidance,
minimization, and withdrawal have not achieved
improved long-term outcomes versus tacrolimus-based
regimens [21], although two studies published in
2003/2004 reported similar efficacy outcomes with
reduced and standard dosing of tacrolimus in combi-
nation with sirolimus [19,22].
The ADHERE Phase IV study was designed to
investigate renal function with once-daily, prolonged-
release tacrolimus-based immunosuppression 1 year
post de novo kidney transplantation. To the authors’
knowledge, this is the first study to assess whether
lower dose prolonged-release tacrolimus plus sirolimus
(started on Day 28 after transplantation) improves
renal function compared with higher dose prolonged-
release tacrolimus plus MMF. This study is also the
first large-scale clinical trial in kidney transplantation
to use a primary endpoint of glomerular filtration rate
measured by iohexol clearance (mGFR).
Patients and methods
Study design
ADHERE was a multicenter, randomized, open-label,
two-arm, parallel-group comparative Phase IV study
conducted at 58 sites in 18 European and Asia–Pacific
countries between March 2011 and September 2013.
The study was conducted in accordance with the Decla-
ration of Helsinki, Good Clinical Practice, International
Conference on Harmonization guidelines, and applica-
ble laws and regulations. An independent ethics com-
mittee granted approval before initiation. Written
informed consent was obtained from all participants.
Eligible patients were ≥18 years old with end-stage
kidney disease, suitable for primary renal transplanta-
tion or retransplantation (unless the graft was lost from
rejection within 6 months), and receiving a kidney
transplant from a deceased or living (nonhuman leuko-
cyte antigen identical) donor with compatible ABO
blood type. Patients were excluded from the study if
they had previously received an organ transplant other
than a kidney, the cold ischemia time was >30 h, or the
panel-reactive antibody grade was >20%. Patients were
also excluded from the study if they received a graft
from a donor after cardiac death (unless the donor was
of Maastricht category 3, that is, withdrawal of support
awaiting cardiac arrest), had significant liver disease, or
required initial sequential or parallel therapy with
immunosuppressive antibody preparation(s) or ongoing
dosing with a systemic immunosuppressive drug prior
to transplantation.
Randomization and masking
The randomization sequence was prepared by Pierrel
Research Europe GmbH, Essen, Germany. Randomiza-
tion was coordinated centrally using an interactive voice
response system (managed by Cenduit GmbH, Allsch-
wil, Switzerland) and block procedure. Eligible patients
were randomized (1:1) on Day 28 following transplan-
tation to receive either prolonged-release tacrolimus
plus MMF (Arm 1) or prolonged-release tacrolimus
(≥25% dose reduction on Day 42) plus sirolimus (Arm
2). Treatment allocation was stratified according to
study center and donor type (deceased or living kidney
donor). Patients who were experiencing an acute-rejec-
tion episode on Day 28 could have randomization
delayed for up to 7 days after the end of treatment for
the rejection episode.
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Procedure
All patients received prolonged-release tacrolimus
(AdvagrafTM; Astellas Pharma Europe BV, Leiden, the
Netherlands) from Day 0 to Day 365 with an initial
postoperative dose of 0.2 mg/kg/day. Doses were taken
once daily, orally, and adjusted based on clinical efficacy
and tolerability, taking into account recommended
whole-blood trough concentrations. Tacrolimus target
trough levels were 10–15 ng/ml until Day 14, then 8–
12 ng/ml from Day 15 to Day 27 in both arms. Pos-
trandomization, Arm 1 tacrolimus target trough levels
were 8–12 ng/ml between Day 28 and 41, and 6–10 ng/
ml from Day 42 until the end of study (EOS). In Arm
2, tacrolimus target trough levels were 8–12 ng/ml
between Day 28 and 41; the tacrolimus dose was then
decreased by ≥25% to target tacrolimus trough levels of
4–5 ng/ml between Day 42 and the EOS.
All patients received oral MMF each day (1 g twice
daily until Day 14, reduced to 0.5 g twice daily until
Day 27). Patients in Arm 1 continued to receive MMF
at a daily dose of 1 g. For patients randomized to Arm 2
only, MMF was discontinued on Day 28; these patients
received sirolimus, orally, once daily from Day 28 to the
EOS, with an initial daily dose of 1 mg and a target
trough level range of 2–4 ng/ml (maximum dose 2 mg
daily). All patients received a single dose of corticos-
teroids, administered as an intravenous bolus of
≤1000 mg on Day 0 in accordance with each center’s
policy. Oral corticosteroids were then tapered through-
out the study (Day 1–13: 20 mg/day, Day 14–28: 15 mg/
day, Day 29–42: 10 mg/day, Day 43–60: 5 mg/day, Day
60–365: ≤5 mg/day). Treatment of cytomegalovirus
(CMV) was in accordance with each center’s policy.
Primary and secondary efficacy variables
The primary endpoint was measured GFR by iohexol
clearance (mGFR) at Week 52 post-transplant. Secondary
efficacy variables included renal function at Week 52:
estimated GFR [eGFR, Modification of Diet in Renal
Disease-4 (MDRD4) and Chronic Kidney Disease
Epidemiology Collaboration (CKD-EPI)] and creatinine
clearance (CrCl) by the Cockcroft–Gault formula. Other
secondary endpoints included the incidence of composite
efficacy failure defined as patient withdrawal or graft loss
(defined as retransplantation, transplant nephrectomy,
death or dialysis ongoing at the EOS or at the time of dis-
continuation); clinical acute rejection (AR) and biopsy-
confirmed AR (BCAR); patient and graft survival; delayed
graft function (DGF) (defined as dialysis ≥1 day during
the first 7 days post-transplant); and new-onset diabetes
mellitus (NODM) as per the American Diabetic Associa-
tion (ADA) 2010 criteria [23].
Subgroup analyses
To assess the possibility that the treatment effect might
differ in specific subgroups of patients, the subgroup-
by-treatment interaction effect was tested in an analysis
of covariance (ANCOVA) model similar to that used for
the primary analysis. In addition, to further explore any
significant subgroup-by-treatment interaction effect,
observed analysis of the primary variable was also
repeated separately for the subgroups of patients strati-
fied by recipient age (<50 years, ≥50 years), donor age
(<50 years, ≥50 years), donor status (deceased, living),
and gender.
Other variables
Additional variables in this study included patient-
reported EuroQoL 5-Dimensions Health Questionnaire
(EQ-5D), assessment of adherence to the study drug
using the Morisky Medication Adherence Scale-8, and
the length and type of hospital stay.
Tolerability analyses
Tolerability was assessed by the evaluation of AEs and
laboratory parameters, which were monitored through-
out the study. Postrandomization AEs were defined as
those with an onset date occurring on or after random-
ization; AEs that changed in severity on or after the date
of randomization were included as postrandomization
AEs. A serious AE was any untoward medical occurrence
that was life threatening, resulted in death, persistent or
significant disability or incapacity, congenital anomaly,
birth defect, or required inpatient hospitalization. The
relationship between the AE and the study medication
was indicated as not related, possible, or probable.
Statistical methods
The safety-analysis set (SAF) was defined as all patients
who took at least one dose of any study drug (pro-
longed-release tacrolimus, MMF or sirolimus). The
intent-to-treat (ITT) population consisted of all patients
who had been transplanted and randomized, and the
full-analysis set (FAS) was defined as all patients who
had been transplanted, randomized, and underwent
postrandomization assessment of the primary endpoint
Transplant International 2017; 30: 83–95 85
ª 2016 The Authors. Transplant International published by John Wiley & Sons Ltd on behalf of Steunstichting ESOT.
mGFR with tacrolimus and sirolimus or MMF
(i.e., evaluable iohexol sample measurements). Analysis
of the primary and secondary efficacy variables on renal
function, and the subgroup and subgroup-by-treatment
interaction analyses, was undertaken on the FAS. Analy-
ses of the nonrenal function secondary efficacy variables
were undertaken on the ITT population. Tolerability
analyses that occurred prior to randomization were per-
formed using the SAF, and analysis of AEs with an
onset date on or after Day 28 was performed using the
ITT population.
To detect a clinically meaningful 6 ml/min increase
in mGFR measured in Arm 2 versus Arm 1 with 90%
power, 284 patients were required to have evaluable
mGFR at Week 52 in each arm. With an assumed drop-
out rate of 16.5% over the 12-month period, it was esti-
mated that 386 patients should be enrolled and
transplanted per arm. The target enrollment of 772
patients had assumed <10% of the patients would fail
to reach randomization; however, the prerandomization
dropout rate was considerably greater than 10%. There-
fore, the recruitment target was increased to 856 in
order to reach the intended number of evaluable
patients. Least square (LS) means of mGFR (FAS) were
obtained from the ANCOVA, and the difference between
the LS means and the 95% confidence intervals (CI) is
presented. P values were derived from an ANCOVA model
in which treatment arm, gender, race (black, nonblack),
site, and donor status (deceased, living) were included
as factors, and eGFR (MDRD4) at randomization and
donor age were included as continuous covariates. A
sensitivity analysis (ANCOVA) of the primary endpoint
was conducted in the ITT population, with imputation
of mGFR for patients with missing iohexol clearance
and for those who experienced graft loss and/or death.
For patients who experienced graft loss, retransplanta-
tion, dialysis at the end of the study, and/or death, the
imputed value was set to zero. For patients with missing
iohexol clearance who did not experience graft loss and/
or death, a multiple imputation procedure was used to
replace each missing value with a set of plausible values
(based on the covariate values at baseline/randomiza-
tion) that represent uncertainty about the correct value
to impute. Similar multiple imputation data sets were
analyzed for the secondary efficacy variables of eGFR
and calculated CrCl using the ITT population. P values
≤0.05 were considered significant for all analyses.
Kaplan–Meier survival analysis techniques were used for
analysis of time-to-event endpoints, and the 95% CI for
the difference between arms was calculated using the
normal approximation method. In addition, the differ-
ences in incidence between arms were compared using a
chi-square test. All data processing, summaries, and
analyses were performed using SAS software version
9.1.3 or higher on UNIX.
Results
Patient and donor demographics
Overall, 850 patients received ≥1 dose of study medica-
tion and were included in the SAF, and 120 patients in
the SAF were excluded from the ITT as they were either
not transplanted (12 patients) or transplanted but not
randomized (108 patients). In total, 730 patients were
included in the ITT (Fig. 1); 625 patients (73.5% of the
SAF) completed the study. Postrandomization, 38
patients in Arm 1 and 67 patients in Arm 2 discontin-
ued from the study; the main reason for discontinua-
tion in both arms was AEs (Arm 1: 5.2%; Arm 2:
14.4%). Figure 2 shows the time and incidence of pos-
trandomization study discontinuations in each arm.
Patient demographics and baseline characteristics in the
ITT were generally comparable between arms. Donors
were mainly ≤65 years old (n = 648, 88.7%), male
(n = 383, 52.5%), and deceased (n = 602, 82.5%). The
overall mean (standard deviation, SD) cold and warm
ischemia times were 10.9 (6.97) h and 38.4 (23.6) min,
respectively, and were similar in both treatment arms.
Recipient and donor baseline characteristics are shown
in Table 1. In total, 569 (77.9%) patients from the ITT
underwent a postrandomization assessment of the pri-
mary endpoint and were included in the FAS (Arm 1:
287; Arm 2: 282).
Dosing and exposure
Mean prolonged-release tacrolimus dose was similar
between arms up to randomization on Day 28 and
remained comparable between arms until Day 42, when,
in line with the ≥25% dose reduction in the study pro-
tocol, the mean dose was lower in Arm 2 versus Arm 1
to the EOS (Fig. 3a). Mean tacrolimus trough levels
were comparable between arms until Day 28 and
remained similar until Day 42; from Day 42 to EOS,
mean trough levels were lower in Arm 2 versus Arm 1
(Fig. 3b). Mean (SD) EOS tacrolimus trough levels were
similar between patients who discontinued due to AEs
in Arm 2 [6.89 (3.44) ng/ml] compared with the overall
Arm 2 population [5.73 (2.56) ng/ml] (including those
who discontinued) (target range: 4–5 ng/ml).
Mean MMF dose was comparable between arms until
Day 28; from Day 28 to EOS, the mean MMF dose
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remained consistent in Arm 1 (~1 g/day). From Day
28, patients in Arm 2 received sirolimus; mean (SD)
sirolimus whole-blood trough levels in the FAS were
3.27 (2.20) ng/ml [median: 2.70 (range: 0.0–14.1) ng/
ml] on Day 28 and 3.73 (1.44) ng/ml (3.50 (1.0–
8.8) ng/ml) at Week 52. Although there was no require-
ment to titrate the sirolimus dose, patients remained
within the target sirolimus trough range (2–4 ng/ml)
except for on Day 56 [4.21 (2.32) ng/ml]. In total,
54.1% of patients in Arm 2 had more than one siroli-
mus dose >1 mg/day between Day 28 and Week 52.
Mean (SD) EOS sirolimus trough levels were 3.29
(1.82) ng/ml for patients who discontinued due to AEs
in Arm 2 compared with 3.68 (1.61) ng/ml for the
overall Arm 2 population. The mean and median daily
doses of sirolimus at the EOS, in patients who with-
drew due to AEs, were 1.29 and 1.0 mg/day, respec-
tively. All randomized patients received steroids; the
mean (SD) steroid cumulative doses were comparable
between arms [Arm 1: 2111 (1450) mg versus Arm 2:
2219 (1503) mg, respectively].
Renal function (primary and secondary endpoints;
FAS)
The primary efficacy endpoint GFR (iohexol clearance)
at Week 52 was comparable between Arm 1 and Arm 2
(LS mean: 40.7 vs. 41.8 ml/min/1.73 m2, respectively;
P = 0.405) (Table 2). When the methods used for the
primary analysis were repeated using the ITT, with
imputed data for patients with missing GFR by iohexol
clearance measurements, similar results were obtained.
The secondary efficacy endpoints comparing renal func-
tion showed no significant differences between arms for
LS means of eGFR (MDRD4: 50.5 vs. 51.0 ml/min/
1.73 m2; P = 0.720; CKD-EPI: 51.5 vs. 51.8 ml/min/
1.73 m2; P = 0.823) or CrCl (Cockcroft–Gault: 56.6 vs.
57.1 ml/min/1.73 m2; P = 0.736) (Table 2).
Other secondary endpoints (ITT/SAF)
Other secondary endpoints (from randomization on Day
28 to Week 52; ITT) and all time-to-event secondary
Figure 1 Flow of patients through the study, including reasons for discontinuation. The numbers presented in the figure are percentages. All
patients received oral MMF until Day 27. For patients randomized to Arm 2 only, MMF was discontinued and sirolimus was initiated on Day 28
and continued throughout the study. FAS, full-analysis set; ITT, intent to treat; MMF, mycophenolate mofetil; SAF, safety-analysis set.
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efficacy endpoints (AR, BCAR, patient and graft survival,
and NODM) were generally comparable between arms at
Week 52 with the exception of composite efficacy failure
(Table 3). The Kaplan–Meier estimate of composite effi-
cacy failure was significantly higher in Arm 2 versus Arm
1 (18.2% vs. 11.5%; P = 0.002). The difference between
arms, postrandomization, was driven by patient with-
drawal due to AEs, which was significantly higher in Arm
2 versus Arm 1 (14.4% vs. 5.2%; P < 0.001). Kaplan–
Meier estimates of DGF including events prior to ran-
domization were 23.1% in nonrandomized patients,
11.9% in Arm 1 and 11.1% in Arm 2 (SAF).
Other outcomes (ITT)
Patient-reported outcomes assessed at Week 52 using
EQ-5D showed no significant differences between arms
(P = 0.711). The changes from baseline on the Visual
Analog Scale, scored from “best imaginable health state”
to “worst imaginable health state,” were similar between
arms, with both arms showing an increase in quality of
life compared with baseline data.
For the patients who were randomized, the mean
number of days in hospital from baseline to EOS was
21.1 in Arm 1 versus 17.4 in Arm 2. A total of 22
patients in Arm 1 were admitted to the intensive care
unit compared with 17 patients in Arm 2. The mean
duration of stay for patients in Arm 1 was 9.9 days
compared with 12.4 days for the patients in Arm 2. A
similar number of patients in Arm 1 and Arm 2 had
dialysis during the study (82 vs. 80 patients, respec-
tively); the mean number of days that patients spent in
hospital on dialysis was 8.6 days in Arm 1 versus
6.9 days in Arm 2. Treatment adherence was high in
both arms, and the majority of patients took their med-
ication regularly.
Subgroup analyses (FAS)
When the FAS was analyzed using similar methods to
the primary analysis, with the treatment-by-donor age
interaction effect included, a significant interaction
effect was observed for the treatment-by-donor age
effect (P = 0.027); however, the overall treatment effect
did not reach statistical significance (P = 0.602). When
the analysis was repeated separately for patient sub-
groups, there were no significant differences in mean
GFR (iohexol clearance) between arms except for
patients with donor age <50 years. In this subgroup
(donor age <50 years), mGFR was significantly higher
in Arm 2 versus Arm 1 (61.9 vs. 57.7; difference:
4.2 ml/min/1.73 m2; P = 0.038).
Tolerability analyses (SAF/ITT)
The incidence of mortality was low overall and compa-
rable between arms. Of the 16 deaths reported, nine
occurred during the study period (six
Figure 2 Incidence of study discontinuations in each arm stratified by time interval postrandomization (ITT). The graph presents postrandom-
ization discontinuation data for all patients who were transplanted and randomized (ITT population). All patients received oral MMF until Day
27. For patients randomized to Arm 2 only, MMF was discontinued and sirolimus was initiated on Day 28 and continued throughout the study;
primary reason for discontinuation (after Day 28): adverse event, Arm 1 n = 19 (5.2%) versus Arm 2 n = 53 (14.4%); withdrawal of consent,
Arm 1 n = 7 (1.9%) versus Arm 2 n = 4 (1.1%); lost to follow-up, Arm 1 n = 3 (0.8%) versus Arm 2 n = 2 (0.5%); retransplantation/graft
loss, Arm 1 n = 2 (0.6%) versus Arm 2 n = 2 (0.5%); protocol violation, Arm 1 n = 1 (0.3%) versus Arm 2 n = 3 (0.8%); not fulfilling inclu-
sion/exclusion criteria, Arm 1 n = 1 (0.3%) versus Arm 2 n = 0; other, Arm 1 n = 5 (1.4%) versus Arm 2 n = 3 (0.8%). ITT, intent to treat;
MMF, mycophenolate mofetil.
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Table 1. Baseline characteristics of recipients and donors in each treatment arm (FAS).
Arm 1: prolonged-release
tacrolimus + MMF (n = 287)
Arm 2: prolonged-release
tacrolimus + sirolimus (n = 282)
Donor
Gender, male, n (%) 153 (53.3) 150 (53.2)
Race, n (%)
White 144 (90.6) 157 (89.7)
Asian 14 (8.8) 17 (9.7)
Other* 1 (0.6) 1 (0.6)
Not recorded 128 107
Mean age, years (SD) 48.2 (15.5) 49.9 (14.5)
Donor type
Living related, n (%) 32 (11.1) 40 (14.2)
Living nonrelated, n (%) 10 (3.5) 13 (4.6)
Deceased, n (%) 245 (85.4) 229 (81.2)
ABO identical†, n (%) 272 (94.8) 260 (92.2)
ABO compatible‡, n (%) 15 (5.2) 22 (7.8)
Mean total HLA mismatch, n 2.87 2.99
CMV recipient/donor, n (%) Negative/negative 35 (12.2) 21 (7.4)
Negative/positive 56 (19.5) 45 (16.0)
Positive/positive 139 (48.4) 166 (58.9)
Positive/negative 47 (16.4) 33 (11.7)
Positive/unknown 2 (0.7) 5 (1.8)
Unknown/positive 5 (1.7) 8 (2.8)
Unknown/negative 3 (1.0) 4 (1.4)
EBV, n (%) Positive 154 (53.7) 161 (57.1)
Mean PRA grade§ (SD) 0.75 (2.8) 0.77 (2.7)
Recipient
Gender, male, n (%) 179 (62.4) 186 (66.0)
Race, n (%)
White 256 (92.4) 251 (91.9)
Asian 18 (6.5) 16 (5.9)
Other* 3 (1.1) 6 (2.2)
Not recorded 10 9
Mean age, years (SD) 49.6 (13.2) 49.2 (13.0)
Mean BMI¶, kg/m2 (SD) 25.3 (4.2) 25.4 (4.3)
Primary reason for kidney
transplantation, n (%)
PKD 62 (21.6) 43 (15.2)
Glomerulonephritis 49 (17.1) 59 (20.9)
HN (including HNy) 32 (11.2) 34 (12.1)
Unknown 31 (10.8) 29 (10.3)
Other** 113 (39.4) 117 (41.5)
HBV, n (%) Positive 6 (2.1) 2 (0.7)
EBV, n (%) Positive 222 (77.4) 223 (79.1)
All patients received oral MMF until Day 27. For patients randomized to Arm 2 only, MMF was discontinued and sirolimus was
initiated on Day 28 and continued throughout the study.
BMI, body mass index; CMV, cytomegalovirus; EBV, Epstein–Barr virus; FAS, full-analysis set; HBV, hepatitis B virus; HLA,
human leukocyte antigen; HN, hypertensive nephrosclerosis; HNy, hypertensive nephropathy; PKD, polycystic kidney disease;
PRA, panel-reactive antibody; SD, standard deviation.
*Other race: Black, Native Hawaiian, Pacific Islander, or other.
†Recipient and donor had the same blood group.
‡A or B recipient received kidney from donor with same or O group; AB recipient received organ from an O, A, or B donor.
§PRA grade: Arm 1, n = 283, Arm 2, n = 281.
¶Recipient BMI: Arm 1, n = 279, Arm 2, n = 278.
**Other reasons for primary kidney transplantation: obstructive uropathy (including chronic pyelonephritis), diabetic nephropa-
thy, IgA nephropathy, tubular and interstitial disease, not recorded, focal segmental glomerulonephritis, membranoproliferative
glomerulonephritis, hereditary nephropathy, systemic lupus erythematosus, other systemic vasculitis.
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prerandomization, three postrandomization), two of
which were considered to be related to treatment
(pneumonia, one patient in each arm). Seven deaths
occurred after the end-of-treatment visit or withdrawal
from the study, but within 1 year post-transplant. In
the whole study period, 205 (24.1%) patients in the
SAF reported ≥1 AE of special interest (NODM, pro-
teinuria, pulmonary complications, mouth ulcers, and
impairment of wound healing).
Prerandomization tolerability analyses (SAF)
A total of 717 (84.4%) patients reported AEs post-trans-
plant but prerandomization. AEs prerandomization
were reported in 304 (84.0%) vs. 314 (85.3%) patients
in Arm 1 versus Arm 2, respectively; 99 (82.5%) of the
120 patients not randomized experienced ≥1 AE, and
six (5%) of these patients died. Causes of death
included bradycardia, pulmonary sepsis, gastrointestinal
disorder, sudden death, operative hemorrhage, and
aortic dissection.
Postrandomization tolerability analyses (ITT)
Postrandomization AEs and study drug-related AEs were
comparable between arms [AEs Arm 1: 307 of 362
(84.8%) versus Arm 2: 309 of 368 (84.0%); study drug-
related AEs Arm 1: 212 of 362 (58.6%) versus Arm 2:
215 of 368 (58.4%)]. The most commonly reported pos-
trandomization adverse events are presented in Table 4.
Postrandomization AEs of special interest were lower in
Arm 1 versus Arm 2 [41 of 362 (11.3%) vs. 70 of 368
(19.0%)]. Postrandomization, Arm 1 versus Arm 2 had
a higher incidence of CMV infection [43 of 362 (11.9%)
vs. 14 of 368 (3.8%)], bacterial urinary tract infection
[33 of 362 (9.1%) vs. 18 of 368 (4.9%)], and leukopenia
[47 of 362 (13.0%) vs. 9 of 368 (2.4%)]. In contrast,
patients in Arm 1 versus Arm 2 had a lower incidence
(a) Mean tacrolimus dose per body weight
(b) Mean tacrolimus whole-blood trough levels
Figure 3 Tacrolimus (a) dose per
body weight and (b) trough levels
stratified by arm over 52 weeks of
treatment (ITT). All patients received
oral MMF until Day 27. For patients
randomized to Arm 2 only, MMF was
discontinued and sirolimus was
initiated on Day 28 and continued
throughout the study and tacrolimus
dose was decreased by ≥25%
between Day 42 and the EOS; error
bars (SD) correspond to visit days
(Days 1, 7, 14, 28, 56, 84, 168, 252,
and 356). ITT, intent to treat; MMF,
mycophenolate mofetil; SD, standard
deviation.
90 Transplant International 2017; 30: 83–95
ª 2016 The Authors. Transplant International published by John Wiley & Sons Ltd on behalf of Steunstichting ESOT.
Rummo et al.
Table 2. Renal function at Week 52 as assessed by primary and secondary endpoints.
Arm 1: prolonged-release
tacrolimus + MMF (n = 287)
Arm 2: prolonged-release
tacrolimus + sirolimus (n = 282) P value*
Primary endpoint
GFR by iohexol clearance (ml/min/1.73 m2)
Mean 40.73 41.75 0.405
Difference† 1.02
95% CI for mean difference –1.39, 3.44
Secondary endpoints
eGFR by MDRD4 (ml/min/1.73 m2)
Mean 50.54 51.03 0.720
Difference† 0.49
95% CI for mean difference –2.21, 3.20
eGFR by CKD-EPI (ml/min/1.73 m2)
Mean 51.46 51.77 0.823
Difference† 0.31
95% CI for mean difference –2.44, 3.07
Calculated CrCl by Cockcroft–Gault (ml/min)
Mean 56.61 57.14 0.736
Difference† 0.53
95% CI for mean difference –2.54, 3.59
All patients received oral MMF until Day 27. For patients randomized to Arm 2 only, MMF was discontinued and sirolimus was
initiated on Day 28 and continued throughout the study.
CI, confidence interval; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; eGFR, estimated glomerular filtration
rate; FAS, full-analysis set; GFR, glomerular filtration rate; LS, least square; MDRD4, modification of diet in renal disease-4;
MMF, mycophenolate mofetil.
*Derived from an ANCOVA model in which treatment arm, gender, race (black, nonblack), site, and donor status (deceased, liv-
ing) were included as factors, and eGFR (MDRD4) at randomization and donor age were included as continuous covariates.
†LS mean difference for Arm 2 minus Arm 1; ANCOVA: analysis of covariance.
Table 3. Kaplan–Meier estimates of secondary efficacy variables at Week 52 (ITT).








(95% CI) P value‡
Composite efficacy failure, n (%) 40 (11.5) 67 (18.2) 6.7 (1.5, 11.9) 0.002
Acute rejection, n (%) 26 (7.3) 30 (8.3) 1.0 (2.9, 4.9) 0.624
BCAR, n (%) 14 (4.3) 13 (3.6) –0.7 (3.6, 2.3) 0.892
Graft loss, n (%) 10 (2.9) 8 (2.2) –0.7 (3.0, 1.6) 0.676
Patient death, n (%) 4 (1.1) 1 (0.3) –0.9 (2.1, 0.4) 0.177
NODM, n (%) 24 (8.5) 36 (12.8) 4.3 (0.9, 9.5) 0.183
All patients received oral MMF until Day 27. For patients randomized to Arm 2 only, MMF was discontinued and sirolimus was
initiated on Day 28 and continued throughout the study.
BCAR, biopsy-confirmed acute rejection; CI, confidence interval; ITT, intent to treat; MMF, mycophenolate mofetil; NODM,
new-onset diabetes mellitus.
*Events that happened at or after Week 52 were grouped into Week 52+.
†Kaplan–Meier survival estimates for the incidence of patients with the event (Arm 2–Arm 1).
‡Wilcoxon–Gehan test.
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of physician-reported diabetes mellitus [14 of 362
(3.9%) vs. 25 of 368 (6.8%)], hyperlipidemia [12 of 362
(3.3%) vs. 24 of 368 (6.5%)], proteinuria [6 of 362
(1.7%) vs. 22 of 368 (6.0%)], and peripheral edema [42
of 362 (11.6%) vs. 66 of 368 (17.9%)]. A total of three
patients in the SAF died postrandomization, two in Arm
1 and one in Arm 2 (Arm 1: acute myocardial infarction
and organizing pneumonia; Arm 2: pneumonia).
Discussion
The results from this large, comprehensive, multicenter
study show that at Week 52, patients maintained similar
renal function with standard-dose, prolonged-release
tacrolimus plus MMF compared with lower dose, pro-
longed-release tacrolimus plus sirolimus. The efficacy
and safety profiles of the immunosuppressive regimens
were generally comparable overall, with similar inci-
dences of graft and patient survival, AR, BCAR, NODM,
and DGF. However, a significantly higher incidence of
composite efficacy failure was reported in Arm 2 (siroli-
mus) versus Arm 1 (MMF); this difference was driven
by a higher number of early withdrawals due to AEs in
Arm 2. Overall, treatment adherence was high in both
arms, and the majority of patients took their medication
regularly.
Mean target tacrolimus trough levels were achieved
early after prolonged-release tacrolimus initiation in both
arms, and tacrolimus trough levels in Arm 1 remained
within the target window throughout the study. In Arm
2, after the protocol-stipulated dose reduction on Day
42, tacrolimus trough levels were lower versus Arm 1
from the next trough level measurement at Day 56, but
remained higher than the targeted 4–5 ng/ml. As there
were 12 days between the 25% dose reduction (Day 42)
and the next trough measurement, and taking assay vari-
ability into consideration, clinicians may have felt that
they could not target the trough level to 4–5 ng/ml with
confidence without more frequent trough measurements.
Potentially ambiguous instruction on the appropriate
procedure in relation to mean trough levels of pro-
longed-release tacrolimus in the protocol could also have
played a role. In Arm 2, sirolimus mean whole-blood
trough levels generally remained within the target range,
although the mean sirolimus dose was >1 mg through-
out the study. Sirolimus trough levels for patients who
discontinued due to AEs were within the target range,
although generally lower than the overall Arm 2 study
population. Mean tacrolimus trough levels for these
patients were above target levels at EOS and higher than
the overall Arm 2 study population.
The primary endpoint of renal function (GFR, mea-
sured by iohexol clearance) and secondary renal func-
tion measures eGFR (MDRD4 and CKD-EPI) and CrCl
(Cockcroft–Gault) were comparable between arms at
Week 52, indicating that a lower dose prolonged-release
tacrolimus/sirolimus-based regimen did not reduce
renal function impairment compared with a standard
prolonged-release tacrolimus/MMF-based regimen.
Compared with earlier studies showing increased
nephrotoxicity with calcineurin inhibitor plus sirolimus-
based regimens [24], this study confirmed no increase
in toxicity with prolonged-release tacrolimus in combi-
nation with low-dose sirolimus, which is encouraging
for clinical practice. Studies carried out previously using
Table 4. Most commonly reported postrandomization
adverse events (≥5% in either treatment arm) from Day












Overall, n (%) 307 (84.8) 309 (84.0)
Diarrhea 47 (13.0) 36 (9.8)
Leukopenia 47 (13.0) 9 (2.4)
Cytomegalovirus
infection
43 (11.9) 14 (3.8)
Edema peripheral 42 (11.6) 66 (17.9)
Escherichia UTI 39 (10.8) 24 (6.5)
Blood creatinine
increased
33 (9.1) 32 (8.7)
UTI bacterial 33 (9.1) 18 (4.9)
Nasopharyngitis 30 (8.3) 29 (7.9)
Tremor 28 (7.7) 26 (7.1)
Cough 24 (6.6) 14 (3.8)
Hypertension 21 (5.8) 22 (6.0)
Renal impairment 21 (5.8) 17 (4.6)
Dyslipidemia 20 (5.5) 22 (6.0)
UTI 20 (5.5) 21 (5.7)
UTI enterococcal 19 (5.2) 26 (7.1)
Anemia 18 (5.0) 22 (6.0)
Kidney transplant
rejection
18 (5.0) 17 (4.6)
Diabetes mellitus 14 (3.9) 25 (6.8)
Hypercholesterolemia 13 (3.6) 22 (6.0)
Hyperlipidemia 12 (3.3) 24 (6.5)
Proteinuria 6 (1.7) 22 (6.0)
All patients received oral MMF until Day 27. For patients ran-
domized to Arm 2 only, MMF was discontinued and sirolimus
was initiated on Day 28 and continued throughout the study.
ITT, intent to treat; MMF, mycophenolate mofetil; UTI,
urinary tract infection.
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twice-daily, immediate-release tacrolimus reported simi-
lar renal function with tacrolimus/MMF and low-dose
tacrolimus/sirolimus-based regimens [19,22].
Iohexol clearance is considered a gold standard for
the measurement of GFR in the evaluation of renal
function, and this was the first large, randomized study
to use iohexol clearance as a primary endpoint in kid-
ney transplantation. Accurate monitoring of renal func-
tion following transplantation is essential [25], and
although iohexol clearance is considered one of the
most accurate methods of assessing renal function, mea-
suring GFR is more complex and time consuming than
estimating GFR. For this reason, previous studies evalu-
ating immunosuppressive regimens have relied on esti-
mates of GFR or CrCl to monitor renal function
[13,21,26]. The accuracy of GFR estimation methods
varies and may be affected by characteristics such as
ethnic group, body mass index, and stage of renal fail-
ure [27,28], making estimated renal function data com-
pared between studies less reliable.
In the subgroup analysis of the primary variable, a
significant interaction effect of treatment-by-donor age
(<50 vs. ≥50 years) was observed, although the overall
interaction effect of treatment-by-donor age as a con-
tinuous variable did not reach statistical significance.
When the analysis was performed separately for each
donor age group, mean GFR at Week 52 was signifi-
cantly higher in Arm 2 versus Arm 1 in only the sub-
group of patients with donor age <50 years. This is in
line with results from a previous study that reported
better outcomes with a tacrolimus/sirolimus-based regi-
men for patients receiving donor kidneys without pre-
existing interstitial fibrosis and tubular atrophy (gener-
ally younger donor age). However, for patients receiv-
ing donor kidneys with interstitial fibrosis and tubular
atrophy (generally older donor age), improved out-
comes were reported with a tacrolimus/MMF-based
regimen [20]. These subgroup analyses were a sec-
ondary comparison of the primary variable and not
adjusted for multiple testing and so should be inter-
preted with caution; however, the data suggest that
specific patient subgroups could potentially benefit
from receiving different prolonged-release tacrolimus-
based immunosuppressive regimens.
The incidence of the composite endpoint of efficacy
failure was significantly higher in Arm 2 versus Arm 1.
This difference was driven by a higher incidence of pos-
trandomization withdrawal due to AEs in Arm 2, as
incidence of graft loss was comparable between arms.
These findings are consistent with other studies that
suggest the clinical usage of sirolimus could be limited
by tolerability issues [16]. However, it should be noted
that although more patients were withdrawn due to AEs
in Arm 2, the number of AEs reported was comparable
between arms. Results from this study showed similar
postrandomization rates of graft and patient survival,
AR and BCAR to previously reported studies using pro-
longed-release tacrolimus [13,29].
A similar number of serious treatment-emergent AEs
thought to be related to the study drugs were reported
in both arms; however, a significantly higher number of
patients (more than twice as many) withdrew perma-
nently from the study due to adverse events in Arm 2
versus Arm 1. A lower incidence of CMV infection was
reported in the sirolimus-treated Arm 2 versus Arm 1.
This is in line with a previous study, which showed that
the rate of CMV infection was higher in patients treated
with a low-dose tacrolimus regimen versus a sirolimus
regimen [21].
This study had a number of limitations. A tacrolimus
plus sirolimus immunosuppressive regimen is not as
widely used as the tacrolimus plus MMF regimen.
Physicians in this open-label study may have felt less
confident in managing patients on this combination,
which might have impacted the incidence of patients in
Arm 2 who were withdrawn early from the study, in
particular, those withdrawn due to AEs. The higher
withdrawal rate in Arm 2 versus Arm 1 should be taken
into consideration when interpreting the primary analy-
sis. In addition, whole-blood tacrolimus trough levels
remained higher than target in Arm 2 from Day 42 to
the EOS.
Overall, data from both arms of this study confirm
that once-daily, prolonged-release tacrolimus-based
immunosuppression is efficacious and has an accept-
able tolerability profile over 52 weeks of treatment in
de novo kidney transplant recipients when used in
combination with MMF or delayed-initiation sirolimus.
Renal function measured by iohexol clearance was
comparable between arms; however, we cannot exclude
that the tacrolimus trough levels that remained higher
than the target in Arm 2 (in combination with siroli-
mus) could have been responsible for renal toxicity.
While the subgroup analysis suggests that specific
groups of patients could benefit from receiving a pro-
longed-release tacrolimus plus sirolimus regimen (e.g.,
recipients with a younger donor), additional studies
would need to be performed to confirm these findings.
However, given the lower incidence of intolerable AEs
leading to patient discontinuation from this study,
prolonged-release tacrolimus plus MMF may be an
improved treatment regimen versus lower dose,
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prolonged-release tacrolimus plus sirolimus, although
the latter regimen provides a viable alternative.
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